Market Overview

The neuroblastoma market was valued at US$ 256.0 million in 2023. Looking ahead, the market in the 7MM is projected to reach US$ 328.2 million by 2032, with a compound annual growth rate (CAGR) of 2.28% from 2024 to 2032.

The neuroblastoma market receives a detailed examination in "Neuroblastoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032". This report delves into the specifics of neuroblastoma, a cancer originating in the immature nerve cells of the sympathetic nervous system, primarily found in areas like the adrenal glands situated above the kidneys, and potentially in other regions such as the neck, chest, abdomen, and pelvis. Typically affecting infants and young children, it occasionally appears in adults. Symptoms often include abdominal lumps leading to discomfort, swelling, and complications such as constipation or difficulty urinating, alongside other signs like bone pain, respiratory issues, unexplained weight loss, fatigue, fever, high blood pressure, and a rapid heartbeat. Diagnosis typically starts with a physical examination and medical history review, followed by various imaging studies and tests to identify the tumor's characteristics and confirm the diagnosis.

Market Drivers and Growth Facilitators

Genetic mutations and chromosomal abnormalities are significant drivers of the neuroblastoma market, contributing to the altered development of nerve cells. Emerging therapies like proton therapy, which minimizes damage to surrounding tissues and is ideal for treating tumors near vital organs, and gene expression profiling (GEP), which helps in identifying the genetic makeup of neuroblastoma, are propelling the market forward. The report highlights the increasing investment in research and development by key players to introduce targeted therapies that spare healthy cells, thereby enhancing clinical outcomes and minimizing side effects. The rising demand for combination therapies, which are more effective than single treatment modalities and reduce resistance risks, is also anticipated to boost market growth in the forecast period.

Geographic and Market Scope

Disease Root Analysis exhaustive analysis encompasses neuroblastoma treatment landscapes across diverse regions including the United States, the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. It explores in-market and pipeline drugs, shares of individual therapies, and the performance of key companies and their drugs. Furthermore, it assesses the current and future patient pool across these major markets, highlighting the United States as the largest market both in terms of patient pool and treatment avenues. The report also examines current treatment practices, market dynamics, reimbursement scenarios, and unmet medical needs.

Recent Developments in the Neuroblastoma Market

Significant recent developments include Essential Pharma's acquisition of Renaissance Pharma and the FDA approval of Panbela Therapeutics’ eflornithine for maintenance therapy in high-risk neuroblastoma cases. Renaissance Pharma's collaborations with St. Jude Children's Research Hospital and NorthStar Medical Radioisotopes' advances in clinical trials for Cu-67 SARTATE are also noteworthy, underscoring ongoing innovation and strategic partnerships in the sector.

Key Highlights and Statistics

Neuroblastoma impacts a notable number of children under 15 annually, with a higher incidence in males and predominant diagnoses by the age of five. It constitutes a significant portion of pediatric cancer-related deaths each year, emphasizing the critical need for effective treatments and ongoing research.

Leading Therapeutic Options

The therapeutic landscape features several prominent drugs like Unituxin, a targeted monoclonal antibody, and Racotumomab, an anti-idiotype cancer vaccine. Another key treatment is Omblastys, a radiopharmaceutical designed for advanced cases involving the brain, spinal cord, or leptomeninges, showcasing the diverse approaches being taken to combat this severe disease.

Neuroblastoma Key companies

USWM

Clarity Pharmaceuticals

Norgine B.V

Y-mAbs Therapeutics

Aptorum Group

EUSA Pharma

Geographies Covered

US,

Germany

France

Italy

Spain

UK

Japan